Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,992,218

« Back to Dashboard
Patent 6,992,218 protects OFIRMEV and is included in one NDA. There has been one Paragraph IV challenge on Ofirmev.

Protection for OFIRMEV has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in fourteen countries.

Summary for Patent: 6,992,218

Title:Method for obtaining aqueous formulations of oxidation-sensitive active principles
Abstract:A method for obtaining aqueous formulations with easily oxidizable active principles, notably phenols, stable over a prolonged period, comprising subjecting them to extreme deoxygenation by bubbling with an inert gas and/or placing wider vaccum, protecting them against possible resorption of oxygen by keeping them under an inert gas atmosphere, by filling, under inert gas, into bottles previously cleared of air by insufflation with inert gas, then subjecting them, while stoppering, to low pressure as obtained in the bottle, of 65,000 Pa maximum, to obtain aqueous solutions having a residual oxygen concentration in the solution below 2 ppm, and preferably of the order of 1 ppm and even 0.5 ppm useful as injectable preparations having an oxygen concentration in the solution below 2 ppm.
Inventor(s): Dietlin; Francois (La Vesinet, FR), Fredj; Daniele (Gif sur Yvette, FR)
Assignee: Pharmatop SCR (FR)
Application Number:10/332,060
Patent Claim Types:
see list of patent claims
Formulation; Process; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 1st percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mallinckrodt Ip
SOLUTION;IV (INFUSION)022450-001Nov 2, 2010RXYes6,992,218*PEDDec 6, 2021Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,992,218

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France00 07231Jun 06, 2000
France00 07231Jun 6, 2000
PCT Information
PCT FiledJune 06, 2001PCT Application Number:PCT/FR01/01749
PCT Publication Date:December 13, 2001PCT Publication Number: WO01/93830

International Patent Family for Patent: 6,992,218

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
France2809619<disabled in preview>
Morocco26926<disabled in preview>
MexicoPA03000001<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.